Inhibrx, Inc. (NASDAQ:INBX) Clinical Momentum Signals Continued Near-Term Strength
Pipeline progress and a fresh clinical update reinforce positive technical momentum, while fundamentals and WMDST valuation show material overvaluation and leverage that constrain upside without clinical execution.







